HESTERBIO · Hester Biosciences Ltd · Biotechnology & Drugs
HESTERBIO · Hester Biosciences Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
11.6% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹77 Cr
Revenue YoY
PAT YoY
+489.9%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
5.3
P/S (TTM)
5.9
Sector P/E
Not available from data source
Dividend yield
+0.5%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| HESTERBIO (this stock) | 13.7 | 5.3 | +41.8% | +37.8% | 0.54 | +0.5% |
| Sun Pharmaceutical Industries | 38.9 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 76.4 | 20.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
falling 2q
MF
0.03% (0.00pp)
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: During the earnings conference call held on July 30, 2026, management of Hester Biosciences Limited reported a 14% growth in standalone revenue from operations and an 88% increase in profit after tax (PAT) for Q1 FY27 compared to the same quarter last year. Gross margins improved from 69% to 78%, attributed to a favorable product mix and operational efficiencies. The Poultry Healthcare Division experienced a significant 48% growth, driven by increased institutional business and market penetration. However, consolidated revenue declined by 8%, primarily due to lower revenues from operations in Nepal and Africa. Management highlighted ongoing efforts in research and development, emphasizing the importance of innovation for long-term growth. They also discussed the challenges faced in international markets and the impact of government-led immunization programs on the Animal Healthcare Division. Overall, management expressed confidence in the company's strategic direction and long-term growth potential.
Management highlighted strong growth in key divisions and ongoing strategic initiatives.
Sourced from an exchange-filed transcript, dated 01 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: During the earnings conference call held on May 15, 2026, management of Hester Biosciences Limited reported a 22% revenue growth for Q4 FY26, with a significant 174% increase in profit after tax (PAT). For the full year, while standalone revenue remained flat, PAT improved by 64%. The Poultry Healthcare division showed strong performance, growing by 41% in Q4 and 21% for the year, aided by new product launches and market penetration. The Animal Healthcare division faced delays in tender programs but saw improved execution in Q4. Management highlighted ongoing investments in R&D and capacity expansion, particularly in the Fill-Finish and BSL-3 facilities. They acknowledged external risks, including raw material cost volatility and tender timing issues, while emphasizing a focus on operational efficiency and long-term growth strategies.
Management reported both strong growth in certain segments and challenges in others.
Sourced from an exchange-filed transcript, dated 18 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The earnings conference call held on January 30, 2026, by Hester Biosciences Limited discussed the financial results for the quarter and nine months ended December 31, 2025. Management reported a 12% revenue growth in Q3, with a significant 140% increase in profit after tax, attributed to a favorable product mix and cost discipline. The Poultry Healthcare division saw a 32% growth in Q3, bolstered by market penetration and demand for vaccines. Management highlighted the receipt of marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine, enhancing their portfolio. However, the Animal Healthcare division faced a 38% decline in Q3 due to delays in government immunization programs. Management emphasized ongoing efforts to reduce reliance on tender-driven revenues and strengthen their market presence. The call concluded with management expressing confidence in sustaining growth and profitability moving forward.
The document presented both positive growth in the Poultry division and challenges in the Animal Healthcare segment.
Sourced from an exchange-filed transcript, dated 02 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedHester Biosciences Limited (HESTERBIO) reported a year of strategic intent and readiness in FY2025-26, marked by expanded product offerings, including new marketing and manufacturing licenses for its H9N2 low pathogenic Avian Influenza vaccine. The company maintained profitability through favorable product mix and disciplined cost management in Africa. Key developments include strengthening scientific capabilities, operational systems, and regulatory compliance. The company has no material defaults, regulatory actions, or liquidity concerns, with statutory auditors affirming the accuracy of financial statements and internal controls. The company has several pending tax disputes but no material adverse findings on its going-concern status.
- Received marketing and manufacturing licenses for H9N2 Avian Influenza vaccine, enhancing poultry health offerings.
- Maintained profitability in Africa through cost discipline and product mix.
- No defaults on loans or borrowings, and no willful defaulter status.
- Pending tax disputes for various years, but no material impact on going-concern status.
- Statutory auditors confirmed accuracy of financial statements and internal controls.
Key takeaway: Hester Biosciences demonstrated strong operational and regulatory performance in FY2025-26, with no major defaults or liquidity issues, though it faces several pending tax disputes.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Default / Covenant Breach (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Default / Covenant Breach
2 occurrencesRecent (last 12 months)
The company's subsidiary, Hester Biosciences Africa Limited, had delays in paying principal on term loans from the Gates Foundation.
Older (3+ years ago)
The company has undisputed statutory dues in arrears for more than six months as of 31 March 2023, except for specific disputes listed.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The company has a contingent liability related to a corporate guarantee given to Hester Biosciences Africa Limited for credit facilities.
Earlier (1-3 years ago)
The company has provided guarantees, loans, or advances to subsidiaries and others, with aggregate amounts granted during the year and balances outstanding as of the balance sheet date, though specific figures are not detailed in the excerpt.
Older (3+ years ago)
The company has a contingent liability of USD 14 million related to a corporate guarantee issued for a subsidiary's credit facilities, and pending income tax claims amounting to unspecified amounts, with appeals ongoing.
Related-Party Transaction
2 occurrencesEarlier (1-3 years ago)
The company provided a USD 14 million corporate guarantee in favor of the Gates Foundation, U.S.A. on behalf of its wholly owned subsidiary, Hester Biosciences Africa Limited, for setting up an animal vaccine manufacturing plant.
Older (3+ years ago)
The company obtained member approval for existing and new material related party transactions with Texas Lifesciences Private Limited (TLPL), a subsidiary, up to ₹ 500 Million during the Annual General Meeting on 23 August 2022.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
2.7% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).